Therapeutic Effect of Epirubicin Combined with Docetaxel for Chemotherapy on Patients After Radical Mastectomy for Breast Cancer
Objective To explore the effect and safety of epirubicin combined with docetaxel for chemotherapy in the treatment of patients after radical mastectomy for breast cancer.Methods 80 patients undergoing radical mastectomy were randomly divided into two groups.After surgery,the reference group was treated with FEC regimen for chemotherapy,and the study group was treated with epirubicin+docetaxel for chemotherapy.The tumor vascular related growth factors,adverse reactions and long-term recurrence rate were compared between the two groups.Results After chemotherapy,the levels of serum VEGF and ANG2 in the study group were lower than those in the reference group(P＜0.05).The incidence of gastrointestinal function damage during chemotherapy in the study group was lower than that in the reference group(P＜0.05).During the 3-year follow-up,the recurrence rate in the study group was 22.50％,lower than 47.50％in the reference group(P＜0.05).Conclusions Epirubicin combined with docetaxel for chemotherapy can significantly inhibit the expressions of tumor vascular related growth factors in patients after radical mastectomy for breast cancer and reduce the risk of postoperative recurrence.
Breast cancerEpirubicinDocetaxelClinical efficacyAdverse reactionRecurrence
国家科技期刊平台
NSTL
万方数据
